Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2025-10-07 DOI:10.1007/s10557-025-07780-4

Naoki Kimoto, Yohei Miyashita, Yutaka Yata, Takeshi Aketa, Masami Yabumoto, Yasushi Sakata, Takashi Washio, Seiji Takashima, Masafumi Kitakaze

{"title":"Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer.","authors":"Naoki Kimoto, Yohei Miyashita, Yutaka Yata, Takeshi Aketa, Masami Yabumoto, Yasushi Sakata, Takashi Washio, Seiji Takashima, Masafumi Kitakaze","doi":"10.1007/s10557-025-07780-4","DOIUrl":null,"url":null,"abstract":"Purpose: Breast cancer affects females from puberty onward, with incidence rates increasing with age. Although metabolic syndrome (MetS) has reportedly increased the incidence of almost all cancers, no clear consensus on the role of MetS in breast cancer development exists. We aimed to clarify the effects of MetS on breast cancer incidence.Methods: To investigate this relationship, we analyzed Japanese healthcare data of females from 2005 to 2020 and examined the incidence of breast cancer. MetS was evaluated based on the Japanese criteria or the NCEP ATP III guidelines at enrollment. Of 1,144,791 participants without missing data in our general public cohort, 32,775 with breast cancer at the beginning of the observation period were excluded; 54,330 participants with breast cancer were identified during the observation period.Results: Both pre-stage MetS and MetS, defined using the Japanese criteria, were associated with the less frequent incidence of breast cancer (hazard ratios [HRs], 0.90; 95% CI, 0.86-0.94; p < 0.005: HR, 0.83; 95% CI, 0.80-0.87; p < 0.005). Furthermore, MetS using NCEP ATP III was associated with the lower HR (0.87: CI, 0.84-0.90; p < 0.005), and the number of the factors from 1 to 5 was gradually associated with the lower HRs. Analysis according to age group revealed that this observation was the most prominent in the < 50-year-old group.Conclusion: MetS is associated with the less frequent breast cancer incidence in females, especially aged < 50 years.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07780-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Breast cancer affects females from puberty onward, with incidence rates increasing with age. Although metabolic syndrome (MetS) has reportedly increased the incidence of almost all cancers, no clear consensus on the role of MetS in breast cancer development exists. We aimed to clarify the effects of MetS on breast cancer incidence.

Methods: To investigate this relationship, we analyzed Japanese healthcare data of females from 2005 to 2020 and examined the incidence of breast cancer. MetS was evaluated based on the Japanese criteria or the NCEP ATP III guidelines at enrollment. Of 1,144,791 participants without missing data in our general public cohort, 32,775 with breast cancer at the beginning of the observation period were excluded; 54,330 participants with breast cancer were identified during the observation period.

Results: Both pre-stage MetS and MetS, defined using the Japanese criteria, were associated with the less frequent incidence of breast cancer (hazard ratios [HRs], 0.90; 95% CI, 0.86-0.94; p < 0.005: HR, 0.83; 95% CI, 0.80-0.87; p < 0.005). Furthermore, MetS using NCEP ATP III was associated with the lower HR (0.87: CI, 0.84-0.90; p < 0.005), and the number of the factors from 1 to 5 was gradually associated with the lower HRs. Analysis according to age group revealed that this observation was the most prominent in the < 50-year-old group.

Conclusion: MetS is associated with the less frequent breast cancer incidence in females, especially aged < 50 years.

查看原文本刊更多论文

代谢综合征发病率与乳腺癌的关系

目的：乳腺癌从青春期开始影响女性，发病率随着年龄的增长而增加。尽管代谢综合征（MetS）据报道增加了几乎所有癌症的发病率，但对于MetS在乳腺癌发展中的作用还没有明确的共识。我们的目的是阐明MetS对乳腺癌发病率的影响。方法：分析2005年至2020年日本女性的医疗保健数据，并对乳腺癌的发病率进行调查。MetS在入组时根据日本标准或NCEP ATP III指南进行评估。在我们的普通公众队列中没有缺失数据的1,144,791名参与者中，32,775名在观察期开始时患有乳腺癌的参与者被排除在外；在观察期间，54,330名乳腺癌患者被确诊。结果：使用日本标准定义的前期MetS和MetS均与乳腺癌发生率较低相关（风险比[hr]， 0.90; 95% CI, 0.86-0.94; p）结论：MetS与女性，尤其是老年女性乳腺癌发生率较低相关

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.